非結核性マイコバクテリア性肺疾患の治療：ATS/ERS/ESCMID/IDSAの公式臨床実践ガイドライン

Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline.

• Charles L Daley
• Jonathan M Iaccarino
• Christoph Lange
• Emmanuelle Cambau
• Richard J Wallace
• Claire Andrejak
• Erik C Böttger
• Jan Brozek
• David E Griffith
• Lorenzo Guglielmetti
• Gwen A Huitt
• Shandra L Knight
• Philip Leitman
• Theodore K Marras
• Kenneth N Olivier
• Miguel Santin
• Jason E Stout
• Enrico Tortoli
• Jakko van Ingen
• Dirk Wagner
• Kevin L Winthrop

抄録

非結核性マイコバクテリア（NTM）は190以上の種と亜種に分類され、その中にはすべての年齢層のヒトに疾患を発症する可能性があり、肺と肺外の両方の部位に影響を及ぼす可能性があるものもある。本ガイドラインでは，最も一般的なNTM病原体である複合体や，成長の遅いNTMと急速に成長するNTMのうち，最も一般的なNTM病原体による成人（嚢胞性線維症やヒト免疫不全ウイルス感染を伴わない）の肺疾患に焦点を当てている．専門家パネルは、国際的に著名な呼吸器内科・感染症学会（ATS、ERS、ESCMID、IDSA）によって慎重に選定され、肺医学、感染症・臨床微生物学、臨床検査医学、患者擁護の専門家が参加した。22のPICO（Population, Intervention, Comparator, Outcome）の各質問を中心にシステマティックレビューが行われ、GRADE（Grading of Recommendations Assessment, Development, and Evaluation）アプローチを用いて推奨事項が策定、執筆、評価された。NTM肺疾患の治療に関する31のエビデンスに基づいた推奨事項が提供されている。本ガイドラインは，感染症や肺疾患の専門家を含め，NTM肺疾患患者をケアする医療従事者が使用することを目的としている。

Nontuberculous mycobacteria (NTM) represent over 190 species and subspecies, some of which can produce disease in humans of all ages and can affect both pulmonary and extrapulmonary sites. This guideline focuses on pulmonary disease in adults (without cystic fibrosis or human immunodeficiency virus infection) caused by the most common NTM pathogens such as complex, , and among the slowly growing NTM and among the rapidly growing NTM. A panel of experts was carefully selected by leading international respiratory medicine and infectious diseases societies (ATS, ERS, ESCMID, IDSA) and included specialists in pulmonary medicine, infectious diseases and clinical microbiology, laboratory medicine, and patient advocacy. Systematic reviews were conducted around each of 22 PICO (Population, Intervention, Comparator, Outcome) questions and the recommendations were formulated, written, and graded using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach. Thirty-one evidence-based recommendations about treatment of NTM pulmonary disease are provided. This guideline is intended for use by healthcare professionals who care for patients with NTM pulmonary disease, including specialists in infectious diseases and pulmonary diseases.

Copyright © The Author(s) 2020. This version published by the European Respiratory Society in the European Respiratory Journal, and jointly with Clinical Infectious Diseases. The articles are identical except for minor stylistic and spelling differences in keeping with each journal's style. Either citation can be used when citing this article.